Important Lp(a) Therapy Watchlist

Abstract

Lp(a)-specific therapy is now a real watchlist, not a current prescription. Pelacarsen is the nearest outcomes readout, olpasiran and lepodisiran have major phase 3 outcomes programs, muvalaplin is the oral contender, and zerlasiran has strong phase 2 lowering. A 2026-05-04 access check found no approved Lp(a)-specific drug and no currently recruiting Southeast Asia/Norway treatment trial that fits this profile. Old 2024 papers now document mild right common-femoral plaque/PAD, which strengthens standard prevention/PCSK9-bridge discussion but still does not create an approved Lp(a)-specific drug route. Until outcomes and approvals arrive, readiness means coronary/valve risk-tier clarity, ApoB/LDL control, smoking/BP control, and PCSK9 discussion with cardiology.

lp(a) · cardiovascular · emerging-therapy · pelacarsen · olpasiran · muvalaplin · lepodisiran · zerlasiran · pcsk9

Lp(a) Therapy Watchlist and Readiness Plan

SearchPlan

Question type: watchlist / future-therapy tracking.
Question: Which Lp(a)-lowering therapies matter in 2026, what milestones are pending, and what can actually be pursued in Southeast Asia or Norway now?
Dag-specific context: Lp(a) 838.6 mg/L, old RPPH papers now document mild right common-femoral plaque/PAD on 2024-01-22, ApoB/LDL already fairly controlled on atorvastatin 20 mg, bleeding risk makes aspirin unattractive, coronary/valve imaging status unknown.
Sources searched: PubMed/ACC summaries, ClinicalTrials.gov API, sponsor/official trial pages, existing KB Lp(a)/imaging topics.
Stop condition: concise active watchlist with phase/status, milestone, and management implication.

Current Readiness Rule

Do not wait passively for Lp(a) drugs, but do not pretend they are ready either. The actionable preparation is:

Document actual disease burden: the 2024 Doppler already documents mild peripheral plaque; CAC/CCTA/echo decide whether there is coronary plaque, chronic coronary disease, or valve disease.
Keep ApoB/LDL low now: Lp(a)-specific therapy will likely be added on top of standard risk-factor control, not replace it.
Control the high-ROI modifiers: smoking cessation and blood-pressure profile probably matter more today than any supplement or speculative off-label move.
Use PCSK9 inhibitors as the current bridge discussion if cardiology treats the documented peripheral plaque/high Lp(a) as enough risk, if coronary imaging documents plaque, or if very-high-risk LDL/ApoB targets are chosen.
Track outcomes, not biomarker hype: 80-95% Lp(a) reduction is impressive, but event reduction, approval label, access, and cost decide practice.

Therapy Watchlist

Agent	Modality	Current status / milestone	Lp(a) lowering signal	What would change management
Pelacarsen / TQJ230	GalNAc antisense oligonucleotide	Phase 3 Lp(a) HORIZON, active not recruiting; ClinicalTrials.gov lists primary completion 2026-06-30; established CVD population, Lp(a) >=70 mg/dL	Earlier phase 2 showed large biomarker lowering; HORIZON is the key event trial	Positive outcomes + approval would likely first apply to established CVD / secondary prevention, not automatically risk-factor-only primary prevention
Olpasiran	siRNA	OCEAN(a)-Outcomes active not recruiting; primary completion listed 2028-03-31. OCEAN(a)-PreEvent recruiting, primary completion listed 2031-10-20	Phase 2 OCEAN(a)-DOSE completed; large reductions support phase 3	Outcomes trial could establish secondary-prevention use; PreEvent is strategically important for people before a first event
Lepodisiran	Long-duration siRNA	ALPACA phase 2 completed; ACCLAIM-Lp(a) phase 3 active not recruiting; primary completion listed 2029-03	ALPACA: up to ~94% time-averaged reduction days 60-180 with 400 mg; durable effect	If outcomes positive, infrequent dosing could be a major practical advantage
Muvalaplin	Oral small molecule, blocks Lp(a) particle assembly	KRAKEN phase 2 completed; further phase 3 evaluation needed	12-week reductions around -48%, -82%, and -86% across 10/60/240 mg arms	Oral route is attractive; still needs outcomes and longer safety data
Zerlasiran / SLN360	siRNA	ALPACAR phase 2 completed; phase 3 not yet the anchor until formally launched/confirmed	>80% reductions through 36 weeks; sustained reductions through 60 weeks in ACC summary	Strong contender, but lower immediate readiness than agents already in phase 3 outcomes trials
PCSK9 inhibitors	Approved injectable LDL-lowering drugs	Available now; not Lp(a)-specific	Usually ~20-30% Lp(a) lowering plus major LDL/ApoB lowering	Best current bridge if plaque/risk tier justifies cost and injections

Trial Status Anchors Checked 2026-05-04

Trial	NCT	Status	Enrollment	Primary completion
Lp(a) HORIZON / pelacarsen	NCT04023552	Active, not recruiting	8,323 actual	2026-06-30
OCEAN(a)-Outcomes / olpasiran	NCT05581303	Active, not recruiting	7,297 actual	2028-03-31
OCEAN(a)-PreEvent / olpasiran	NCT07136012	Recruiting	11,000 estimated	2031-10-20
ALPACA / lepodisiran phase 2	NCT05565742	Completed	320 actual	completed
ACCLAIM-Lp(a) / lepodisiran outcomes	NCT06292013	Active, not recruiting	17,300 estimated	2029-03

Access Map Checked 2026-05-04

Region	What is actually available now	Practical meaning
Cambodia / Thailand	No approved Lp(a)-specific drug found. ClinicalTrials.gov search found no active Thailand drug-treatment trial for pelacarsen, olpasiran, lepodisiran, muvalaplin, or zerlasiran; only a completed Novartis observational Lp(a)-in-CVD study in Bangkok/Chiang Mai.	Nothing to travel for now unless a cardiologist is using standard LDL/ApoB drugs such as PCSK9 inhibitors for plaque/LDL-target reasons.
Singapore	No current therapeutic Lp(a)-lowering outcome trial found. Signals found: completed lepodisiran/LY3819469 early-phase healthy-participant work, LILAC Lp(a) education study enrolling by invitation, and an active-not-recruiting hospital-staff Lp(a) study.	Singapore is a reasonable future specialist/access hub after approval, but not a current treatment-trial route for this profile.
Norway	HORIZON/pelacarsen and OCEAN(a)-Outcomes/olpasiran had Norway sites in Oslo/Skedsmokorset but are active-not-recruiting and require established ASCVD. OCEAN(a)-PreEvent is the primary-prevention-relevant olpasiran trial, but listed countries are Australia, Canada, and the US, not Norway. ACCLAIM-Lp(a)/lepodisiran has no Norway site in the ClinicalTrials.gov location list checked.	Norway is useful for lipid-clinic review and future EU/Norway rollout monitoring, not for enrolling now. If imaging documents plaque/ASCVD, Norway/Oslo lipid clinic discussion becomes more relevant.

Current classification: WATCH / no active sourcing action. The near-term action remains disease-burden documentation and standard prevention optimization, not trial-chasing. Re-check trial geography after the pelacarsen readout/regulatory filings or if a new recruiting primary-prevention trial opens in Norway/Singapore/Thailand.

Dag-Specific Implications

Known mild peripheral plaque/PAD (2024 Doppler): strengthens standard prevention intensity and PCSK9-bridge discussion, but does not by itself create an available Lp(a)-specific therapy route.
If no coronary plaque / CAC=0 / normal echo: peripheral plaque still matters, but first Lp(a)-specific labels may still focus on established CVD definitions; cardiology wording matters.
If CAC>0 or CCTA coronary plaque: the argument for PCSK9 bridge therapy and very aggressive ApoB/LDL targets strengthens further while waiting for Lp(a)-specific approval.
If obstructive CAD / chronic coronary disease: Lp(a)-specific therapy becomes much more likely to fit early approval labels if outcomes trials are positive.
If aortic valve sclerosis/stenosis is present: track whether outcome programs include valve endpoints or whether separate valve-focused evidence emerges; do not assume ASCVD outcome benefit automatically solves valve disease.
Aspirin remains separate: Lp(a) therapy watchlist does not change the current no-aspirin primary-prevention rule while GI bleeding risk is unresolved.

What to Watch Next

Pelacarsen HORIZON readout: first major yes/no test for whether large Lp(a) lowering reduces events.
Regulatory label wording: established ASCVD only vs broader high-risk primary prevention; Lp(a) threshold; LDL/ApoB requirements; safety exclusions.
OCEAN(a)-Outcomes and ACCLAIM-Lp(a): confirm whether siRNA class effects translate to outcomes.
OCEAN(a)-PreEvent: most relevant to people before a first major event, but not near-term.
Local/regional access after approval or a relevant recruiting trial: the 2026-05-04 check found no approved Lp(a)-specific drug and no currently recruiting Southeast Asia/Norway therapeutic trial suitable for this profile; the newly found mild PAD record does not change access today.

Key Takeaways for This Profile

Lp(a)-specific therapy is plausible soon, but not actionable until outcomes/approval/access exist.
Pelacarsen is the near-term event-readout to watch; olpasiran and lepodisiran are larger later outcomes anchors.
Muvalaplin is important because it is oral, but still biomarker-stage.
PCSK9 inhibitors remain the only current pharmacologic bridge with both ApoB/LDL lowering and modest Lp(a) lowering.
The 2026-05-04 access check says: no trial-chasing now. Norway has closed/not-recruiting ASCVD trials; Singapore/Thailand have no current suitable therapeutic Lp(a) trial found.

Research Trace

Research date: 2026-05-04.
Sources searched: ClinicalTrials.gov API, PubMed review/current-status pass, ACC/trial summaries, sponsor/official trial pages, existing KB Lp(a)/imaging topics.
Query summary: pelacarsen HORIZON NCT04023552; olpasiran OCEAN(a)-Outcomes / PreEvent; muvalaplin KRAKEN; lepodisiran ALPACA / ACCLAIM; zerlasiran ALPACAR; country filters for Norway, Thailand, Singapore.
Evidence anchors: ClinicalTrials.gov NCT04023552, NCT05581303, NCT07136012, NCT05565742, NCT06292013; Singapore signals NCT04914546, NCT07177612, NCT06304415; Thailand completed observational signal NCT03887520; current-status review PMID: 40430570; PCSK9/Lp(a) review evidence PMID: 41549171, PMID: 41175045, PMID: 40841123; pelacarsen/olpasiran/pipeline anchors PMID: 41102962, PMID: 41879443, PMID: 40821459.
Open gaps: outcome results, approval labels, cost/access, whether primary-prevention high-Lp(a) without plaque qualifies, and whether Norway/Singapore/Thailand gain recruiting primary-prevention trials or early-access routes after regulatory filings.